Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405029 | 0.76 | TP53 (0.38) | ALDH1A1MAPTTSHRMAPK1 | |
| SCHEMBL6606259 | 0.75 | CTNNB1 (0.46) | MAPT | |
| SCHEMBL4264178 | 0.70 | ALDH1A1 (0.75) | ALDH1A1MAPTPKMRXFP1L3MBTL1 | |
| SCHEMBL29550875 | 0.70 | ALDH1A1 (1.00) | ALDH1A1MAPTPKMRXFP1KDM4E | |
| SCHEMBL532500 | 0.70 | ALDH1A1 (1.00) | ALDH1A1MAPTPKMRXFP1KDM4E | |
| SCHEMBL10652999 | 0.70 | MAPT (0.78) | ALDH1A1MAPTPKMRXFP1KDM4E | |
| SCHEMBL4291442 | 0.70 | ALDH1A1 (0.75) | ALDH1A1MAPTPKMRXFP1KDM4E | |
| SCHEMBL4293569 | 0.70 | ALDH1A1 (0.60) | ALDH1A1MAPTPKMRXFP1L3MBTL1 | |
| SCHEMBL4724873 | 0.69 | ALDH1A1 (0.73) | ALDH1A1MAPTPKMRXFP1KDM4E | |
| Hydrochloric Acid SCHEMBL4265299 | 0.69 | ALDH1A1 (0.73) | ALDH1A1MAPTPKMRXFP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | ALDH1A1 945/4885MAPT 4864/4885PKM 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.